Drug Type T-lymphocyte cell therapy |
Synonyms- |
Target- |
Mechanism T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Smart Immune SASStartup |
Active Organization Smart Immune SASStartup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 2 | US | Smart Immune SASStartup | 31 Dec 2021 |
Acute Myeloid Leukemia | Phase 2 | US | Smart Immune SASStartup | 31 Dec 2021 |
Refractory Acute Leukemia | Phase 2 | US | Smart Immune SASStartup | 31 Dec 2021 |